10 Stocks Jim Cramer Discussed As He Questioned Official Data

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders In Q1 2025: 99

Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck’s well-known cancer treatment, KEYTRUDA. The gains were a much-needed boost to the stock, which is still down by 5.6% year-to-date, as the firm has struggled to grow revenue in a turnaround effort led by CEO Albert Bourla. Cramer lamented that Pfizer Inc. (NYSE:PFE)’s stock didn’t move higher on the news:

“Bladder cancer. Now that is left over from the Seagen. The Seagen deal, that was supposed to be very, very important. They spent a fortune on Seagen. And I thought the [inaudible] I thought would be a little more just positive. People are not buying the stock. People just feel like, Pfizer comes up with good thing, good thing, good thing, and no one seems to, David, take it as gospel.”

Cramer discussed Pfizer Inc. (NYSE:PFE) ahead of its earnings:

“There’s another one, that I’m not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It’s enough time to see more than we’ve seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.”